AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE. https://ift.tt/eA8V8J
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment